Includes bibliographical references

Part I. Animal Models for central nervous tumors -- Modeling gliomas using PDGF-expressing retroviruses -- Modeling brain tumors using avian retroviral gene transfer -- Using neurofibromatosis type 1 mouse models to understand human pediatric low-grade gliomas -- Transgenic mouse models of CNS tumors: using genetically engineered murine models to study the role of p21 Ras in glioblastoma multiforme -- PTEN-deficient mouse models for high-grade astrocytomas -- The Nfl-/+; Trp53-/+cis mouse model of anaplastic astrocytoma and secondary glioblastoma : dissecting genetic susceptibility to brain cancer -- Modeling astrocytomas in a family of inducible genetically engineered mice : implications for preclinical cancer drug development -- Human brain tumor cell and tumor tissue transplantation models -- Transformed human brain cells in culture as a model for brain tumors -- Rat glioma models for preclinical evaluation of novel therapeutic and diagnostic modalities -- Neuro-oncogenesis induced by nitroso compounds in rodents and strain-specific genetic modifiers of predisposition -- The murine GL261 glioma experimental model to assess novel brain tumor treatments -- Spontaneous occurrence of brain tumors in animals: opportunities as preclinical model systems --

Part II. Prognostic factors and biomarkers -- p53 pathway alterations in brain tumors -- The PTEN/P13 kinase pathway in human glioma -- Value of 1p/19q and other LOH markers for brain tumor diagnosis, prognosis, and therapy -- Discovery of genetic markers for brain tumors by comparative genomic hybridization -- Genomic identification of significant targets in brain cancer -- Oncomodulatory role of the human cytomegalovirus in glioblastoma -- Aberrant EGFR signaling in glioma -- Mechanisms of brain tumor angiogenesis -- Vaso-occlusive mechanisms that intiate hypoxia and necrosis in glioblastoma: the role of thrombosis and tissue factor -- Transcription profiling of brain tumors: tumor biology and treatment stratification -- Proteomic profiling of human brain tumors -- Proteomic discovery of biomarkers in the cerebrospinal fluid of brain tumor patients -- Epigenetic profiling of gliomas -- Micronase in the central nervous system and potential roles of RNA interference in brain tumors -- Of Escherichia coli and man : understanding glioma resistance to temozolomide therapy -- Brain tumor stem cell markers --

Part III. Therapeutic targets and targeting approaches -- Clinical agents for the targeting of brain tumor vasculature -- Bone marrow-derived cells in GBM neovascularization -- Vascular targeting of brain tumors--bridging the gap with phage display -- Impact of the blood-brain barrier on brain tumor imaging and therapy -- Targeting CXCR4 in brain tumors -- Molecular targeting of IL-13R[alpha]2 and EphA2 receptor in GBM -- Molecular targets for antibody-mediated immunotherapy of malignant glioma -- Stat3 oncogenic signaling in glioblastoma multiforme -- Inhibition of Ras signaling for brain tumor therapy -- HGF/c-Met signaling and targeted therapeutics in brain tumors -- Combinatorial therapeutic strategies for blocking kinase pathways in brain tumors -- Targeting the TRAIL apoptotic pathways for glioblastoma therapies -- The NF-[kappa]B signaling pathway in GBMs : implications for apoptotic and inflammatory responses and exploitation for therapy -- Targeting endoplasmic reticulum stress for malignant glioma therapy -- Brain cancer stem cells as targets of novel therapies -- The use of retinoids as differentiation agents against medulloblastoma -- Herpes simplex virus 1 (HSV-1) for glioblastoma multiforme therapy -- The development of targeted cancer gene-therapy adenoviruses for high-grade glioma treatment -- Harnessing T-cell immunity to target brain tumors -- Glioma invasion : mechanisms and therapeutic challenges.